在肺腺癌中由BRAF和MEK抑制剂诱导的布鲁加达表
Leonardo Portolan1, Alessandro Ruzzarin1, Francesca Vassanelli1
1Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.
Journal of cardiovascular electrophysiology
|December 10, 2024
概括
药物诱导的布鲁加达模式管理具有挑战性. 这一案例突出显示,一个肺癌患者接受BRAF和MEK抑制剂的布鲁加达表号复制,使治疗复杂化.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 布鲁加达模式是一种心电图 (ECG) 发现,与心脏突然死亡风险增加有关.
- 药物诱导的布鲁加达模式带来了诊断和管理方面的挑战.
- 转移性肺腺癌需要复杂的瘤疗法.
研究的目的:
- 报告一种药物诱导的1型布鲁加达.
- 讨论针对性治疗的转移性肺腺癌患者的后果.
主要方法:
- 一个66岁的男性患者的病例报告.
- 电心电图 (ECG) 分析.
- 用BRAF和MEK抑制剂进行瘤治疗的审查.
主要成果:
- 患者在心电图上产生了1型布鲁加达表.
- 在开始治疗转移性肺腺癌的BRAF和MEK抑制剂治疗后,这种表现出现了.
结论:
- BRAF和MEK抑制剂可以诱导1型布鲁加达色谱.
- 在接受这些向治疗的癌症患者中,仔细的心电图监测至关重要.
更多相关视频
相关概念视频
MAPK Signaling Cascades
5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


